Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Open Access
- 2 May 2024
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 25 (6) , 719-751
Abstract
Opinion statement: The internal tandem duplication (ITD) mutation of the FMS-like receptor tyrosine kinase 3 (FLT3-ITD) is the most common mutation observed in approximately 30% of acute myeloid leukemia (AML) patients. It represents poor prognosis due to continuous activation of downstream growth-promoting signaling pathways such as STAT5 and PI3K/AKT. Hence, FLT3 is considered an attractive druggable target; selective small FLT3 inhibitors (FLT3Is), such as midostaurin and quizartinib, have been clinically approved. However, patients possess generally poor remission rates and acquired resistance when FLT3I used alone. Various factors in patients could cause these adverse effects including altered epigenetic regulation, causing mainly abnormal gene expression patterns. Epigenetic modifications are required for hematopoietic stem cell (HSC) self-renewal and differentiation; however, critical driver mutations have been identified in genes controlling DNA methylation (such as DNMT3A, TET2, IDH1/2). These regulators cause leukemia pathogenesis and affect disease diagnosis and prognosis when they co-occur with FLT3-ITD mutation. Therefore, understanding the role of different epigenetic alterations in FLT3-ITD AML pathogenesis and how they modulate FLT3I’s activity is important to rationalize combinational treatment approaches including FLT3Is and modulators of methylation regulators or pathways. Data from ongoing pre-clinical and clinical studies will further precisely define the potential use of epigenetic therapy together with FLT3Is especially after characterized patients’ mutational status in terms of FLT3 and DNA methlome regulators.Keywords
Funding Information
- Abdullah Gul University
This publication has 240 references indexed in Scilit:
- The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next‐generation sequencing in adult acute myeloid leukemia patients with the FLT3‐ITD mutationHematological Oncology, 2023
- Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemiaAmerican Journal of Hematology, 2021
- Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutationsCancer, 2020
- Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid LeukemiaAmerican Journal of Hematology, 2018
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AMLAmerican Journal of Hematology, 2015
- Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid LeukemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological dataGenes, Chromosomes and Cancer, 2012
- Epigenetic Regulation of Cancer Stem Cell Marker Cd133 by Transforming Growth Factor-βHepatology, 2010
- Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cellsJournal of Leukocyte Biology, 1999